Alector, Inc. (ALEC): R&D Expense
$123.06M
Year ended 2025-12-31
$99.13M
Trailing 12 months to 2026-06-30
-16.4%
3-year compound annual growth
-4.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $123.06M | -33.8% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $185.94M | -3.2% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $192.12M | -8.7% | 2025-02-26, From 2023-01-01 |
| 2022-12-31 | $210.42M | +11.1% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $189.41M | +20.7% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $156.87M | +56.0% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $100.53M | +37.7% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $73.03M | +144.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $29.91M | n/a | 2020-03-24, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | $123.06M | -33.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $18.67M | -37.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $261.38M | -18.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗